Department of Anaesthesiology, Hospital São Teotónio, Viseu, Portugal.
Pharmacology. 2011;88(3-4):182-7. doi: 10.1159/000330740. Epub 2011 Sep 27.
Tramadol, a central analgesic acting on serotonin neurotransmission, is often co-used with ondansetron, a 5-HT(3) antagonist, for the management of postoperative pain to decrease nausea and vomiting. The aim of the study is to test the hypothesis that this drug combination raises tramadol requirement by patient-controlled analgesia (PCA). Forty patients undergoing hernioplasty or thyroidectomy were enrolled in a randomized, controlled study and allocated to receive ondansetron 4 mg i.v. (n = 20) or saline (n = 20). At 0, 1, 2, 4 and 24 h of PCA, tramadol consumption was evaluated. Tramadol consumption (mg × kg(-1) × h(-1)) was higher in the ondansetron group at the 2-hour time point compared to the control group (0.24 ± 0.1 vs. 0.17 ± 0.16; p = 0.01). Our study suggests that ondansetron acutely reduces the analgesic efficacy of tramadol.
曲马多通过作用于 5-羟色胺递质起到中枢镇痛作用，常与昂丹司琼（5-HT3 拮抗剂）联合用于术后镇痛以减少恶心和呕吐。本研究旨在检验曲马多联合昂丹司琼通过患者自控镇痛（PCA）增加曲马多需求量的假设。40 例行疝修补术或甲状腺切除术的患者参与了一项随机对照研究，并被分配接受昂丹司琼 4mg iv（n = 20）或生理盐水（n = 20）。在 PCA 的 0、1、2、4 和 24 小时，评估曲马多的消耗量。与对照组相比，昂丹司琼组在 2 小时时点的曲马多消耗量（mg × kg(-1) × h(-1))更高（0.24 ± 0.1 比 0.17 ± 0.16；p = 0.01）。我们的研究表明昂丹司琼可使曲马多的镇痛效果急性减弱。
